Overview

The Effect of Ketamine on the Length of Hospital Stay of Patients Hospitalized With Suicidal Ideation.

Status:
Terminated
Trial end date:
2017-05-19
Target enrollment:
0
Participant gender:
All
Summary
This study will evaluate the effect of ketamine on the treatment of patients hospitalized with suicidal thoughts. Half of the patients will receive one dose of ketamine in the vein. The other half will receive a placebo. Because we think that ketamine will improve depression and suicidal thoughts, we expect that patients who receive ketamine will require less time in the hospital than patients who receive placebo.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Allen Richert
University of Mississippi Medical Center
Treatments:
Ketamine
Criteria
Inclusion Criteria:

1. Men and women between the ages of 18 and 64

2. Patients admitted to the University of Mississippi Medical Center inpatient psychiatry
service with suicidal ideations

Exclusion Criteria:

1. Lifetime history of schizophrenia or other primary psychotic disorder

2. Current psychotic or manic symptoms

3. Substance use disorder within one month of admission

4. Positive urine toxicology at admission

5. Any lifetime abuse of ketamine or phencyclidine

6. Systolic BP >180 mmHg or diastolic BP >110 mmHg

7. Any patient who has eaten food within 8 hours prior to receiving the ketamine infusion
or who has drank clear liquids within 2 hours prior to receiving the infusion

8. Known central nervous system (CNS) mass

9. CNS abnormalities

10. Hydrocephalus

11. Glaucoma

12. Acute globe injury

13. Porphyria

14. Untreated thyroid disease

15. Known coronary artery disease with poor functional capacity

16. Pregnancy

17. Currently breast-feeding